Robert Grunsten, MD
Psychiatry · Chicago, ILNPI 1740393313
Payments from drug & device makers
Across 89 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$397
- Takeda Pharmaceuticals U.S.A., Inc.$249
- Otsuka America Pharmaceutical, Inc.$236
- Shire North American Group Inc$127
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$114
- Sunovion Pharmaceuticals Inc.$81
- plus $113 from 5 others
What the payments were for
- Food & beverage$1,13887%
- Education$17713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $397 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $249 |
| Otsuka America Pharmaceutical, Inc. | 16 | $236 |
| Shire North American Group Inc | 9 | $127 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $114 |
| Sunovion Pharmaceuticals Inc. | 4 | $81 |
| Neurocrine Biosciences, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
How this compares
$1,315 in reported general payments places this provider in the 75th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 14 | $10,072 |
| Aripiprazole | 20 | $2,289 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 41 | $1,400 |
| Bupropion XlBupropion Hcl | 43 | $1,228 |
| Quetiapine Fumarate | 24 | $1,107 |
| Buspirone Hcl | 73 | $1,106 |
| Vilazodone Hcl | 11 | $1,063 |
| Alprazolam | 157 | $932 |
| Clonazepam | 106 | $883 |
| Duloxetine Hcl | 19 | $827 |
| Trazodone Hcl | 70 | $724 |
| Escitalopram Oxalate | 44 | $712 |
| Lorazepam | 66 | $617 |
| Olanzapine | 18 | $581 |
| Zaleplon | 57 | $496 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Chicago
- Yuhwen ChowChicago$8.5M
- Jon GrantChicago$1.4M
- Jeffrey RadoChicago$1.2M
- Mitchell GlaserChicago$1.1M
- Peter WeidenChicago$941K
- Brett PlylerChicago$293K
- Michelle DeesChicago$289K
- Jennifer SpragueChicago$288K
- K Ranga KrishnanChicago$92K
- Pawel DudekChicago$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.